A biotechnology company developing stem cell therapies to treat neurodegenerative diseases
Our proprietary technology converts mesenchymal stem cells into NurOwn®, a biological drug delivery system designed to support damaged neurons
NurOwn® cells dampen the immune system and secrete growth factors that help damaged neurons survive.
BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
April 11, 2018BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York
April 9, 2018Letter To Shareholders
March 28, 2018BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients
BrainStorm is proceeding with a randomized, double-blind, placebo-controlled multi-dose Phase 3 trial that is being conducted at multiple U.S. sites.
For more information on enrollment, contact one of the participating clinical trial sites.
Additional information can be found on clinicaltrials.gov under identifier (NCT number): NCT03280056.